Parion Sciences and Takeda End Collaboration on P-321 for Ophthalmic Indications

Durham, North Carolina – October 31, 2019 – Parion Sciences, Inc. today announced the termination of the License Agreement dated April 28, 2017 between Parion and Shire (now Takeda Pharmaceutical Company Limited) that granted Shire exclusive worldwide rights to develop and commercialize P-321.  As a result of the termination, Parion regains exclusive development and commercial rights to P-321 for all indications.

READ THE ENTIRE PRESS RELEASE HERE ►